Status: Recruiting
A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis
This trial adopts a multicenter, open-label, positive drug parallel control clinical trial design, planning to enroll approximately 75 MF participants. Eligible participants will be stratified and assigned in a 1:1:1 ratio to the low-dose flonoltinib maleate tablet group, high-dose flonoltinib maleate tablet group, or the ruxolitinib tablet group. Stratification factor include the Dynamic International Prognostic Scoring System (DIPSS) risk classification (intermediate-2 and high risk)
Participants needed: 75
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Chengdu Zenitar Biomedical Technology Co., LtdUpdated: Apr 10, 2025Locations: 2
Eligibility criteria
Age ≥ 18 years, no gender restrictions; [+6]
Previous anticancer treatment-related toxic reactions have not recovered to grad... [+19]